Medicine & Life Sciences
Graft vs Host Disease
100%
Primary Myelofibrosis
76%
Cell Transplantation
57%
Allogeneic Cells
53%
National Institutes of Health (U.S.)
36%
Survival
36%
INCB018424
25%
Stem Cell Transplantation
24%
Transplants
23%
Transplantation
22%
Quality of Life
22%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
19%
Mortality
18%
Patient Reported Outcome Measures
17%
Acute Myeloid Leukemia
16%
Polycythemia Vera
15%
Busulfan
15%
Bone Marrow
14%
Bronchiolitis Obliterans
14%
Neoplasms
14%
Multiple Myeloma
13%
Therapeutics
13%
Confidence Intervals
12%
Clinical Trials
12%
Hematopoietic Stem Cell Transplantation
12%
Danazol
11%
Myelodysplastic Syndromes
11%
venetoclax
11%
Skin
10%
Cell- and Tissue-Based Therapy
9%
Chimeric Antigen Receptors
9%
Azacitidine
9%
fludarabine
9%
Janus Kinase Inhibitors
8%
Cytarabine
8%
Comorbidity
7%
Homologous Transplantation
7%
Survivors
7%
Rituximab
7%
Steroids
7%
Non-Hodgkin's Lymphoma
7%
Lung
7%
RG7388
7%
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6%
Melphalan
6%
Karyotype
6%
Consensus
6%
GATA2 Deficiency
6%
Recurrence
6%
Practice Guidelines
6%